Skip to main content
profile image
Selected Works of Philip Mease, MD
Presentation
16-week placebo-controlled data from Phase III psoriatic arthritis (PsA) studies do not indicate an increased risk of suicidal ideation and behaviour (SIB) events in patients treated with brodalumab. 26th Congress European Academy of Dermatology and Venereology (EADV), Geneva, Sept. 2017
26th Congress European Academy of Dermatology and Venereology (EADV) (2017)
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Link
Disciplines
Publication Date
September, 2017
Citation Information
Philip Mease and et.al.. "16-week placebo-controlled data from Phase III psoriatic arthritis (PsA) studies do not indicate an increased risk of suicidal ideation and behaviour (SIB) events in patients treated with brodalumab. 26th Congress European Academy of Dermatology and Venereology (EADV), Geneva, Sept. 2017" 26th Congress European Academy of Dermatology and Venereology (EADV) (2017)
Available at: http://works.bepress.com/philip-mease/214/